Danielle Henry

ORCID: 0000-0001-8851-7968
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Telomeres, Telomerase, and Senescence
  • Breast Cancer Treatment Studies
  • interferon and immune responses
  • Epigenetics and DNA Methylation
  • SARS-CoV-2 detection and testing
  • Gut microbiota and health
  • Genetics, Aging, and Longevity in Model Organisms
  • Oral microbiology and periodontitis research
  • Breast Lesions and Carcinomas
  • HER2/EGFR in Cancer Research
  • Genetic Associations and Epidemiology
  • Ear and Head Tumors
  • Traumatic Brain Injury Research
  • Cancer Treatment and Pharmacology
  • Family and Disability Support Research
  • MRI in cancer diagnosis
  • Long-Term Effects of COVID-19
  • Breast Implant and Reconstruction
  • Inclusion and Disability in Education and Sport
  • Bariatric Surgery and Outcomes
  • Advanced Radiotherapy Techniques
  • Genomics and Chromatin Dynamics
  • Pluripotent Stem Cells Research

Orlando Health
2016-2024

Orlando Regional Medical Center
2016-2024

Jewish General Hospital
2020-2023

McGill University
2020-2022

Institute for Research in Immunology and Cancer
2020-2021

Université de Montréal
1982-2021

UF Health Cancer Center
2018-2021

University of Florida Health
2018-2021

Moffitt Cancer Center
2018

Virginia Commonwealth University
2007

niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français étrangers, laboratoires publics privés.

10.1051/rphysap:019820017011070700 article FR Revue de Physique Appliquée 1982-01-01

Abstract Telomere erosion in cells with insufficient levels of the telomerase reverse transcriptase ( TERT ), contributes to age‐associated tissue dysfunction and senescence, p53 plays a crucial role this response. We undertook genome‐wide CRISPR screen identify gene deletions that sensitized p53‐positive human inhibition. uncovered previously unannotated gene, C16ORF72 , which we term Attrition Response 1 TAPR1 exhibited synthetic‐sick relationship loss. A subsequent ‐disrupted reciprocally...

10.1111/acel.13331 article EN cc-by Aging Cell 2021-03-04

Abstract Predicting COVID-19 severity is difficult, and the biological pathways involved are not fully understood. To approach this problem, we measured 4701 circulating human protein abundances in two independent cohorts totaling 986 individuals. We then trained prediction models including clinical risk factors to predict 417 subjects tested these a separate cohort of 569 For severe COVID-19, baseline model age sex provided an area under receiver operator curve (AUC) 65% test cohort....

10.1038/s41598-023-31850-y article EN cc-by Scientific Reports 2023-04-17

The precise relationship between epigenetic alterations and telomere dysfunction is still an extant question. Previously, we showed that eroded telomeres lead to differentiation instability in murine embryonic stem cells (mESCs) via DNA hypomethylation at pluripotency-factor promoters. Here, uncovered telomerase reverse transcriptase null (Tert-/-) mESCs exhibit genome-wide chromatin accessibility gene expression during differentiation. These changes were accompanied by increase of H3K27me3...

10.7554/elife.47333 article EN cc-by eLife 2020-04-16

Abstract Proteins detectable in peripheral blood may influence COVID-19 susceptibility or severity. However, understanding which circulating proteins are etiologically involved is difficult because their levels be influenced by itself and also subject to confounding factors. To identify influencing severity we undertook a large-scale two-sample Mendelian randomization (MR) study, since this study design can rapidly scan hundreds of reduces bias due reverse causation confounding. We...

10.1101/2020.10.13.20212092 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2020-10-14
Guillaume Butler‐Laporte Edgar Gonzalez‐Kozlova Chen-Yang Su Sirui Zhou Tomoko Nakanishi and 95 more Elsa Brunet‐Ratnasingham David Morrison Lætitia Laurent Jonathan Afilalo Marc Afilalo Danielle Henry Yiheng Chen Julia Carrasco-Zanini Yossi Farjoun Maik Pietzner Nofar Kimchi Zaman Afrasiabi Nardin Rezk Meriem Bouab Louis Petitjean Charlotte Guzman Xiaoqing Xue Chris Tselios Branka Vulesevic Olumide Adeleye Tala Abdullah Noor Almamlouk Yara Moussa Chantal DeLuca Naomi Duggan Erwin Schurr Nathalie Brassard Madéleine Durand Diane M. Del Valle Ryan C. Thompson Mario A. Cedillo Eric E. Schadt Kai Nie Nicole W. Simons Konstantinos Mouskas Nicolas Zaki Manishkumar Patel Hui Xie Jocelyn Harris Robert Marvin Esther Cheng Kevin Tuballes Kimberly Argueta Ieisha Scott Charuta Agashe Priyal Agrawal Alara Akyatan Kasey Alesso-Carra Eziwoma Alibo Kelvin Alvarez Angelo Amabile Carmen Argmann Kimberly Argueta Steven Ascolillo Rasheed Bailey Craig Batchelor Noam D. Beckmann Aviva G. Beckmann Priya Begani Jessica Le Bérichel Dusan Bogunovic Swaroop Bose Cansu Cimen Bozkus Paloma Bravo Mark Buckup Larissa Burka Sharlene Calorossi Lena Cambron Guillermo Carbonell Gina Carrara Mario A. Cedillo Christie Chang Serena Chang Alexander W. Charney Steven T. Chen Esther Cheng Jonathan Chien Mashkura Chowdhury Jonathan H. Chung Phillip Comella Dana Cosgrove Francesca Cossarini Liam Cotter Arpit Dave Travis Dawson Bheesham D. Dayal Diane M. Del Valle Maxime Dhainaut Rebecca Dornfeld Katie Dul Melody Eaton Nissan Eber Cordelia Elaiho Ethan Ellis Frank Fabris

Abstract Introduction Severe COVID-19 leads to important changes in circulating immune-related proteins. To date it has been difficult understand their temporal relationship and identify cytokines that are drivers of severe outcomes underlie differences between sexes. Here, we measured 147 proteins during acute investigate these questions. Methods We protein abundances using the SOMAscan nucleic acid aptamer panel two large independent hospital-based cohorts Canada United States. fit...

10.1186/s12014-022-09371-z article EN cc-by Clinical Proteomics 2022-09-28

Abstract Secretory variant invasive ductal carcinoma is not well described in the literature but defined by its unique histopathology. These tumors stain positive for S100 and are typically triple negative hormonal cancers with an overall good prognosis. There speculation that secretory adults more aggressive a greater likelihood tumor recurrence. We present two case studies of this rare histopathologic diagnosis. First, 76-year-old female recurrent variant, left breast. Second, 68-year-old...

10.1158/1538-7445.sabcs23-po3-20-10 article EN Cancer Research 2024-05-02

Abstract Predicting COVID-19 severity is difficult, and the biological pathways involved are not fully understood. To approach this problem, we measured 4,701 circulating human protein abundances in two independent cohorts totaling 986 individuals. We then trained prediction models including clinical risk factors to predict adverse outcomes 417 subjects tested these a separate cohort of 569 For severe COVID-19, baseline model age sex provided an area under receiver operator curve (AUC) 65%...

10.1101/2021.10.04.21264015 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2021-10-05

The human brain is a very powerful tool. It allows usto see, remember, understand, and learn. With newtechnologies being discovered every day, scientistsare able to discover how people acquire, process,and store information. New technologies such asmagnetic resonance imaging (MRIs) allow scientistunderstand the reacts particularstimulus or structure can affect person’shealth personality.The nervous system works hand-in-handand coexist in order function everyday life. Thestudy of...

10.20545/isctj.v04.i12.02 article EN International Supply Chain Technology Journal 2018-12-04

Abstract Background: Pertuzumab, a monoclonal antibody targeting subdomain II of HER2 and blocking dimerization, was approved by the FDA in 2013 as neoadjuvant therapy combination with trastuzumab + chemotherapy for HER2+ locally advanced or early-stage breast cancer patients (pts). TCHP (Docetaxel/Carboplatin/Trastuzumab/Pertuzumab) is popular, non-anthracycline therapy. In TRYPHAENA trial, pathologic complete response (pCR) rate 63.6% 6 cycles (47.5% ER+/PR+ 81.1% ER-/PR- tumors). We...

10.1158/1538-7445.sabcs20-ps10-42 article EN Cancer Research 2021-02-15
Coming Soon ...